🇺🇸 Leuprorelin acetate in United States

411 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 66 reports (16.06%)
  2. Nausea — 47 reports (11.44%)
  3. Prostate Cancer — 44 reports (10.71%)
  4. Anaemia — 43 reports (10.46%)
  5. Asthenia — 38 reports (9.25%)
  6. Death — 38 reports (9.25%)
  7. Interstitial Lung Disease — 38 reports (9.25%)
  8. Off Label Use — 35 reports (8.52%)
  9. Prostatic Specific Antigen Increased — 32 reports (7.79%)
  10. Diarrhoea — 30 reports (7.3%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Leuprorelin acetate approved in United States?

Leuprorelin acetate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Leuprorelin acetate in United States?

Takeda is the originator. The local marketing authorisation holder may differ — check the official source linked above.